Related Experiment Video

Updated: Oct 15, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Glucose-insulin-potassium solutions improve outcomes in diabetics who have coronary artery operations

H L Lazar1, S Chipkin, G Philippides

  • 1Department of Cardiothoracic Surgery, Boston Medical Center and Boston University School of Medicine, Massachusetts 02118, USA.

The Annals of Thoracic Surgery
|August 2, 2000
PubMed

Insights

Glucose-insulin-potassium (GIK) therapy improved heart function and reduced complications in diabetic patients undergoing coronary artery bypass grafting (CABG). GIK treatment led to faster recovery and shorter hospital stays for these patients.

Area of Science:

  • Cardiology
  • Metabolic Medicine
  • Surgical Outcomes

Background:

  • Coronary artery bypass grafting (CABG) in diabetic patients presents unique challenges.
  • Assessing interventions to improve myocardial performance and reduce morbidity post-CABG is critical.

Purpose of the Study:

  • To investigate the efficacy of glucose-insulin-potassium (GIK) in enhancing myocardial performance.
  • To determine if GIK administration limits postoperative morbidity in diabetic patients undergoing CABG.

Main Methods:

  • A prospective randomized trial involving 40 diabetic patients undergoing CABG.
  • Patients were assigned to receive either GIK infusion or standard care (no-GIK) for 12 hours postoperatively.
  • GIK solution comprised D5W, regular insulin, and potassium chloride.

Main Results:

  • The GIK group exhibited significantly higher postoperative cardiac indices (p < 0.0001) and lower inotrope scores (p = 0.05).
  • GIK treatment resulted in less weight gain (p < 0.0001) and reduced duration of ventilator support (p = 0.0128).
  • Patients receiving GIK had a lower incidence of atrial fibrillation (p = 0.003) and shorter hospital stays (p = 0.02).

Conclusions:

  • Substrate enhancement with GIK significantly improves myocardial performance in diabetic patients post-CABG.
  • GIK administration facilitates faster recovery and reduces complications, including atrial fibrillation and prolonged ventilation.
  • This intervention offers a promising strategy for optimizing outcomes in diabetic patients undergoing cardiac surgery.
Abstract

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: &#945;-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetic Ketoacidosis l: Introduction01:25

Diabetic Ketoacidosis l: Introduction

DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...